Abstract
Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 235-241 |
| Number of pages | 7 |
| Journal | Trends in Immunology |
| Volume | 29 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2008 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Vascular targeting, chemotherapy and active immunotherapy : teaming up to attack cancer. / Bellone, Matteo; Mondino, Anna; Corti, Angelo.
In: Trends in Immunology, Vol. 29, No. 5, 05.2008, p. 235-241.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vascular targeting, chemotherapy and active immunotherapy
T2 - teaming up to attack cancer
AU - Bellone, Matteo
AU - Mondino, Anna
AU - Corti, Angelo
PY - 2008/5
Y1 - 2008/5
N2 - Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.
AB - Chemotherapy has been combined with therapeutic tumor-specific vaccination in an attempt to simultaneously debulk tumors, increase the effector lymphocyte:tumor cell ratio, and favor immune-mediated tumor rejection. However, chemotherapy is often inadequate because of insufficient and uneven drug penetration into tumors, and because it might also cause, in some instances, undesirable side effects and immunosuppression. Here, we suggest a combined approach based on targeted alteration of the endothelial barrier function with vascular disrupting agents, such as tumor necrosis factor-α (TNF-α), before chemotherapy and tumor-specific vaccination. This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-α and active immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=42749085280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42749085280&partnerID=8YFLogxK
U2 - 10.1016/j.it.2008.02.003
DO - 10.1016/j.it.2008.02.003
M3 - Article
C2 - 18375183
AN - SCOPUS:42749085280
VL - 29
SP - 235
EP - 241
JO - Trends in Immunology
JF - Trends in Immunology
SN - 1471-4906
IS - 5
ER -